WILMINGTON, N.C. & LANSDALE, Pa. -- (BUSINESS WIRE) -- Pharmaceutical Product Development, LLC (PPD) and ProtonMedia today announced that PPD® 3D earned the Gold Award for Best Use of Virtual Worlds for Learning from the Brandon Hall Group Excellence in Learning, Talent Management, and Sales and Marketing Awards.
PPD 3D is a virtual, interactive employee training environment that enhances how PPD prepares clinical research associates to monitor clinical trials. Simultaneously, from any location, learners using customizable avatars can talk, send instant messages, view and interact with presentation and media content, record notes, collaborate to solve problems and accomplish group tasks. Using PPD 3D generates time savings, reduces travel and training costs, and can contribute to faster project startup.
“Comprehensive employee learning and development programs allow PPD to deliver value and quality throughout the drug discovery and development continuum,” said Mike Wilkinson, PPD’s executive vice president and chief information officer. “PPD 3D gives clinical research teams a more engaging and productive way to communicate with colleagues and clients around the world. Improving the way clinical research associates are trained to monitor clinical trials is a prime example of how PPD is continually searching for efficiencies that bring results for clients.”
The PPD 3D environment delivers the benefits of a physical learning space, while allowing attendees to participate fully without traveling to a central location. Post-training survey results demonstrate that PPD 3D is more effective than traditional online training, with 85 percent of respondents noting they were more engaged with this training than with conventional Web-based tools. PPD uses this learner-centered, interactive, engaging and sustainable virtual platform to implement global training, collaboration and performance enhancement initiatives throughout its employee training and development programs.
“PPD and ProtonMedia demonstrated a commitment to advancing employee learning through development of the PPD 3D virtual world,” said Ron Burns, chief executive officer of ProtonMedia. “By combining the robust virtual elements of ProtonMedia’s ProtoSphere technology with PPD’s learning and development expertise, this team strengthened one of the industry’s most acclaimed clinical research associate training programs.”
In addition to the Brandon Hall Gold Award, PPD and ProtonMedia have earned multiple accolades for PPD 3D, including a Microsoft Life Sciences Innovation Award and a Scrip Intelligence award for Best Technological Development in Clinical Trials.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
ProtonMedia is the developer of ProtoSphere, the market-leading virtual collaboration environment for the high-performance workplace, and the #1 virtual environment for collaborative product life cycle management in life sciences. ProtoSphere’s virtual environment provides an arsenal of business-focused collaboration and communication tools that help companies accelerate decision-making and raise productivity, improving workplace performance overall. The company is a Gartner “Cool Vendor in the High-Performance Workplace.” For more information, visit www.protonmedia.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about the Brandon Hall Gold Award and the effectiveness of PPD’s training programs, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; the ability to attract, integrate, retain and training key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.